Introduction
============

Thyroid cancer is one of the most common types of malignancy of the endocrine system ([@b1-ol-0-0-5447]). Anaplastic thyroid carcinoma (ATC), one of the four types of thyroid carcinoma, is an uncommon but aggressive malignancy in older adults, with a morbidity rate of 1.0--7.5%, however, it accounts for 14--39% of thyroid carcinoma-associated mortality and the mean survival duration of ATC is usually \<6 months from diagnosis ([@b2-ol-0-0-5447]). Although certain novel treatment methods, including surgery, genetic therapy and differentiation therapy, provide possibilities for the treatment of ATC ([@b3-ol-0-0-5447]), there is no effective systemic therapy for ATC. Therefore, it is important to examine the molecular mechanisms of ATC and identify several treatment methods for patients with a diagnosis of ATC.

The etiology of ATC remains to be fully elucidated. Previous studies have demonstrated that ionizing radiation, abnormal iodine intake, genetic factors and autoimmune disease are the primary factors contributing to the progression of ATC ([@b4-ol-0-0-5447]). Passaro *et al* ([@b5-ol-0-0-5447]) reported that ionizing radiation enhances the cell death of oncolytic adenovirus dl922-947 in ATC. Increased iodine intake contributes to a lower incidence of ATC ([@b6-ol-0-0-5447]), and it has been reported that forkhead box o3a enhances the proliferation of ATC cells via regulating the transcription factor, cyclin A1 ([@b7-ol-0-0-5447]). In addition, several pathways involved in the progression of ATC have been identified, including the Notch1 signaling pathway, phosphoinositide 3-kinase/Akt signaling pathway and the epidermal growth factor receptor/extracellular signal-regulated kinase pathway ([@b8-ol-0-0-5447]--[@b10-ol-0-0-5447]).

With developments in biology, several studies have focussed on to the mechanism of ATC. Consequently, several biomarkers have been identified for its treatment. For example, paired-box gene 8 may be a useful biomarker for ATC ([@b11-ol-0-0-5447]). In a study by Kim *et al* ([@b12-ol-0-0-5447]) L1 cell adhesion molecule was found to be overexpressed in patients with ATC and it may be an important therapeutic target for ATC treatment. In addition, the mutation of TP53 and expression of SRY-box 2 are associated with the progression from papillary thyroid carcinoma (PTC) to ATC ([@b13-ol-0-0-5447]). However, the mechanism underlying ATC remains to be fully elucidated.

Microarray analysis is an effective approach to monitor global alterations of gene expression and identify the genes important to ATC. Several studies have been performed using the mRNA expression profile, GSE33630, of thyroid carcinoma. For example, Hébrant *et al* ([@b14-ol-0-0-5447]) found that ATC and PTC overlapped. He *et al* ([@b15-ol-0-0-5447]) analyzed 13 genes and one pathway associated with ATC. In addition, Xu *et al* found nine genes and one miscRNA, which were identified as candidates for the progression of thyroid cancer ([@b16-ol-0-0-5447]). However, the latent pathway interactions of ATC remain to be fully elucidated. Thus, using the same samples, the present study aimed to analyze the differentially expressed genes (DEGs) and significant pathways of ATC. Comprehensive bioinformatics analysis was used to enrich the significant functions and pathways of the DEGs to provide detailed insight into the biological mechanisms of ATC. This approach was used to predict the hub genes most likely associated with ATC. The present study aimed to provide a basis for further investigation of the mechanism of ATC.

Materials and methods
=====================

### Data resources and data preprocessing

The GSE33630 gene expression profile data was downloaded from the Gene Expression Omnibus database (<https://www.ncbi.nlm.nih.gov/geo/>) from the National Center for Biotechnology Information based on the platform of the GPL570 Affymetrix Human Genome U133 Plus 2.0 array. The present study included a total of 105 samples, which comprised 11 ATC samples, 49 PTC samples and 45 normal thyroid (NT) samples. The 11 ATC samples and 45 NT samples were selected for analysis in the present study.

The CEL files were transformed into the expression value matrix using the Affy package in R ([@b17-ol-0-0-5447]), and the probe information was then transformed into the gene name using Bioconductor in R ([@b18-ol-0-0-5447]). If one gene had more than one probe, the mean expression value of this gene was selected.

### DEG screening and enrichment analysis

The Limma package ([@b19-ol-0-0-5447]) in R language was used to select the DEGs in the ATC samples, compared with the NT samples. \|log2 fold-change\|\>2 and adjusted P\<0.05 were selected as the threshold values.

Gene Ontology (GO) analysis has become a commonly used approach for functional investigations of large-scale genomic or transcription data ([@b20-ol-0-0-5447]). The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database contains information regarding how molecules or genes are networked, which provides complementary information to the majority of the existing molecular biology databases containing information on individual genes ([@b21-ol-0-0-5447]). The Database for Annotation, Visualization and Integrated Discovery (DAVID) bioinformatics resources consist of an integrated biological knowledge base and analytic tools aimed at systematically extracting biological meaning from large gene or protein lists ([@b22-ol-0-0-5447]). In the present study, the GO functions and pathways of the selected DEGs were enriched using DAVID in the GO (<http://www.geneontology.org>) and KEGG (<http://www.genome.ad.jp/kegg/>) databases with the adjusted P-value (q-value) of \<0.05.

### PPI interaction network construction and selection of significant modules

The PPI interactive pairs of the screened DEGs were selected using the STRING online database (<http://string-db.org/>) ([@b23-ol-0-0-5447]). The DEG interactive pairs with a combined score of \>0.8 were selected for the PPI network construction. Cytoscape (<http://www.cytoscape.org/>) was used to construct the PPI interaction network ([@b24-ol-0-0-5447]). The MCODE plugin was used to select the significant modules associated with ATC from the PPI interaction network ([@b25-ol-0-0-5447]). In addition, the GO terms and pathways of the DEGs in significant modules were enriched using DAVID ([@b22-ol-0-0-5447]) with P\<0.05.

### Latent pathway identification analysis (LPIA)

LPIA, developed by Pham *et al* ([@b26-ol-0-0-5447]), is a method for identifying the interactions of pathways associated with DEGs. A significant interaction represents a correlation between pathways and disease. The LPIA process was as follows: i) GO biological process (BP) terms (G) and KEGG pathways (P) of the DEGs were calculated using clusterProfiler ([@b27-ol-0-0-5447]) in R. ii) A bipartite network was constructed between G and P, one edge of the node was G and the other edge of node was P, with an edge representing one gene involved in G and P, the weight of the edge was determined by the relative overlap of G and P, which was calculated using Jaccard similarity coefficient and the mean expression value for the expression of each DEG. The formula to determine the weight was as follows:
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where P represents the pathway, G represents the GO BP term of each gene, DE represents the expression value of the DEG,

$\left| \frac{G \cap P}{G \cup P} \right|$ is the Jaccard similarity coefficient of G and P and $G \cup P$ is the total DEGs associated with G and P. iii) Based on the bipartite network, the pathways connected with at least one BP term were selected to construct the pathway network. The formula used for the weight of the edge was as follows:
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iv\) The random walk method ([@b28-ol-0-0-5447]) was used to calculate the interaction of each pathway pair, and the significant interactions were selected. The transfer matrix of the random walk method was as follows:
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N~*p*~ represents the total pathways in the network, T*~ij~* represents the probability of one pathway between Pi and Pj.

The process was repeated using the bootstrap method ([@b29-ol-0-0-5447]) steps 1--4, following which the significant P-value of the interaction was obtained.

Results
=======

### Data preprocessing and screenong of DEGs

A total of 19,944 expression probes were obtained from the GSE33630 gene expression profile. The preprocessed data is shown in [Fig. 1A and B](#f1-ol-0-0-5447){ref-type="fig"}. The median values indicated that the data were well normalized.

In addition, 665 genes in the ATC samples, which were differentially expressed compared with the NT samples were screened, which comprised 380 upregulated and 285 downregulated DEGs.

### GO functions and pathways enrichment analysis of DEGs

The GO terms and pathways of all the selected DEGs were enriched using clusterProfiler with P\<0.05 ([Table I](#tI-ol-0-0-5447){ref-type="table"}). The enriched GO terms for the upregulated DEGs in ATC included cellular processes, membrane part and protein binding, whereas single-organism cellular process, extracellular region part and microtubule binding were enriched terms for the downregulated DEGs. In addition, the upregulated DEGs were involved in glycerophospholipid metabolism and metabolic pathways ([Table IA](#tI-ol-0-0-5447){ref-type="table"}), whereas the downregulated DEGs were involved in cytokine-cytokine receptor interaction and the complement and coagulation cascades pathway ([Table IB](#tI-ol-0-0-5447){ref-type="table"}).

### PPI interaction network and significant modules

A PPI interaction network of the DEGs was constructed using STRING. A total of four significant modules with the top five node degree were selected ([Fig. 2A-D](#f2-ol-0-0-5447){ref-type="fig"}). Functional enrichment analysis for the four modules found that no GO term or pathway was enriched by genes in module D. The enriched GO terms and pathways of the DEGs in these significant modules are shown in [Table II](#tII-ol-0-0-5447){ref-type="table"}.

### Interaction analysis between pathways

A total of 406 pathway pairs associated with the DEGs were selected, which were involved in 29 pathways ([Fig. 3](#f3-ol-0-0-5447){ref-type="fig"}; [Table III](#tIII-ol-0-0-5447){ref-type="table"}). Edges with a high weight indicated a higher level of interaction between two pathways. The interactive pathway pairs with the top five weights are shown in [Table IV](#tIV-ol-0-0-5447){ref-type="table"}. hsa04620 interacted with several pathways with high weights, including hsa05323, hsa05142 and hsa05146, indicating hsa04620 was an important pathway. hsa04060 was also identified as an important pathway, which interacted with several other pathways. As shown in [Table IV](#tIV-ol-0-0-5447){ref-type="table"}, FBJ murine osteosarcoma viral oncogene homolog (FOS) was the DEG present in hsa04620, the Toll-like receptor (TLR) signaling pathway and COL5A1 was the DEG present in hsa04512 (ECM-receptor interaction). Certain cytokines, including CXCL12, CXCL3, interleukin (IL)8, CXCL10 and CCL28, were the genes involved in hsa04060 (cytokine-cytokine receptor interaction pathway).

Discussion
==========

ATC is an aggressive malignancy of older adults with a low morbidity rate, but a high mortality rate ([@b2-ol-0-0-5447]). Investigating the mechanism of ATC is beneficial to the treatment and diagnosis of ATC. In the present study, the key genes and significant pathways associated with ATC were analyzed using ATC and NT samples from the GSE33630 gene expression profile. Several key genes, including CXCL10, FOS, COL5A1 and IL8, and the TLR signaling pathway, ECM-receptor interaction and cytokine-cytokine receptor interaction pathway, in which these key genes were involved, were identified using LPIA. However, due to the different selection methods and samples, the findings of the present study were different from those of previous studies, which used the same gene expression profile (GSE33630) of thyroid cancer. Hébrant *et al* ([@b14-ol-0-0-5447]) reported that a more marked EMT was the qualitative difference between PTC and ATC, by examining 11 ATC and 48 PTC samples in GSE33630. He *et al* ([@b15-ol-0-0-5447]) found that the p53 signaling pathway, which included 13 genes, was important for thyroid cancer using gene set enrichment and meta-analysis. Xu *et al* ([@b16-ol-0-0-5447]) selected the BCL2, MRPS31, ID4, RASAL2, DLG2, MY01B, ZBTB5, PRKCQ, PPP6C genes and an miscRNA on considering NT, ATC and PTC together. Therefore, further experimental validation is required.

Certain types of cancer are associated with inflammatory or infectious diseases, and inflammatory factors are associated with ATC. CXCL10 is a chemokine, which produces a ligand for the receptor, CXCR3, and has a paralog of CXCL9 ([@b30-ol-0-0-5447]). Graves\' disease is an autoimmune thyroid disorder of thyroid cancer ([@b31-ol-0-0-5447]). The pathogenesis of autoimmune thyroiditis and Graves\' disease have been associated with the secretion of CXCL10 stimulated by T helper 1 lymphocytes ([@b32-ol-0-0-5447]). In addition, Antonelli *et al* ([@b33-ol-0-0-5447]) confirmed that human ATC cells produce CXCL10 under the effect of certain cytokines. Thus, autoimmune thyroiditis may contribute to the progression of ATC via the secretion of CXCL10. By contrast, the TLR signaling pathway may act as the novel target for the therapy of inflammatory-associated disease ([@b34-ol-0-0-5447]), however, the role of the TLR signaling pathway in ATC remains to be fully elucidated. Mardente *et al* ([@b35-ol-0-0-5447]) reported that the late inflammatory cytokine, high-mobility group box 1, can signal danger to the immune system via the TLR in PTC cell growth. The serum levels of CXCL10 are high in patients with Graves\' disease, and CXCL10 and CXCL9 are important in the recruitment of thyroid cells ([@b36-ol-0-0-5447]). The data obtained in the present study showed that the TLR signaling pathway interacted with the cytokine-cytokine pathway, and the downregulated expression of CXCL10 was involved in the two pathways. This indicated that these two pathways were important in the progression of ATC and that CXCL10 may act as a therapeutic target of ATC.

The present study also showed that the downregulation of IL-8 was important in module B and in the TLR signaling pathway, suggesting it may be important to ATC. IL-8 is a CXC chemokine, which has the antimicrobial functions, and can activate the chemotaxis of neutrophils, T lymphocytes and eosnophils ([@b37-ol-0-0-5447]). Several cytokines have been found to be associated with thyroid cancer. The transfection of IL-12 in the thyroid can potentially inhibit tumor growth and may be a potential tumor vaccine ([@b38-ol-0-0-5447]). In a study by Kobawala *et al* ([@b39-ol-0-0-5447]) the serum levels of IL-8 in patients with ATC were higher, compared with those in healthy individuals, and it may be a target for the diagnosis and therapeutic treatment of ATC. The findings of the present study indicated that the downregulation of IL-8 assisted in the evasion of immune surveillance, leading to ATC. Therefore, IL-8 may be a biomarker for the diagnosis of ATC.

FOS is a member of the FOS family, which acts as a regulator of cell proliferation, differentiation and apoptotic cell death ([@b40-ol-0-0-5447]). The role of FOS in ATC remains to be fully elucidated, however, studies have demonstrated that c-FOS can bind to the promoter, cellular FLICE-inhibitory protein, to function in prostate cancer cells ([@b41-ol-0-0-5447]). c-FOS signaling is regulated by protein kinase R in the promotion of cell proliferation in hepatocellular cancer ([@b42-ol-0-0-5447]). The cell proliferation instability-related gene cluster is an important factor in ATC transformation ([@b43-ol-0-0-5447]). Thus, the FOS protein may be crucial in ATC formation. In the present study, the upregulation of FOS was present in the TLR signaling pathway, suggesting that FOS may be important in contributing to ATC formation via the TLR signaling pathway.

ECM is a protein, which is crucial in thyroid tumor invasion, metastasis and diagnosis ([@b44-ol-0-0-5447]). COL, a low abundance fibrillar collagen of the COL family, is a component of ECM ([@b45-ol-0-0-5447]). The activity of base membrane COL4 indicates the cell proliferation and metastatic abilities of thyroid cancer ([@b46-ol-0-0-5447]). Kusunoki *et al* ([@b47-ol-0-0-5447]) showed that the level of COL4 collagenase in patients with thyroid cancer was higher, compared with that in the normal thyroid, and COL4 may assist in predicting the invasion and metastasis of thyroid cancer. The expression of COL5A1 is suppressed by microRNA-145 in anaplastic meningionas ([@b48-ol-0-0-5447]). Downregulated COL5A1 can decrease the adhesion of tumor cells via the ECM-receptor interaction pathway, enhancing tumor metastasis ([@b49-ol-0-0-5447]). COL11A1 and COL5A1 promote cell migration and tumor progression in mice ([@b50-ol-0-0-5447]). In the present study, the findings showed that COL5A1 and COL11A1 were downregulated and were present in the ECM-receptor interaction pathway, suggesting that the two genes may be important in the progression of ATC via the ECM-receptor interaction pathway.

In conclusion, the present study analyzed the key genes and significant pathways in ATC, compared with NT samples. The TLR signaling pathway, ECM-receptor interaction and cytokine-cytokine receptor interaction pathway were found to be closely associated with ATC. CXCL10 may be of benefit in ATC treatment, FOS may be involved in ATC formation, COL5A1 and COL11A1 may promote the progression of ATC, and IL8 may act as a biomarker for the diagnosis of ATC. The results of the present study provide a basis for further clinical molecular target therapy experiments for ATC.

This study was supported by the National Natural Science Foundation of China (grant no. 81372860).

![Box figure of gene expression data prior to and following normalization. (A) Data prior to normalization; (B) Data following normalization. The horizontal axis represents the sample and the vertical axis represents the expression value. Black lines indicate the median values. Blue represents the control samples and red represents the anaplastic thyroid carcinoma samples. The vertical axes represent expression signal values.](ol-13-01-0167-g05){#f1-ol-0-0-5447}

![Modules containing the top five node degrees in the protein-protein interaction network. Red indicates upregulated DEGs, purple indicates downregulated DEGs. Modules A-D are the four significant modules. DEGs, differentially expressed genes. Lines between DEGs represent interactions between them.](ol-13-01-0167-g06){#f2-ol-0-0-5447}

![Interaction network of the pathways involved with the differentially expressed genes. Lines between DEGs represent interactions between them.](ol-13-01-0167-g07){#f3-ol-0-0-5447}

###### 

Top five enriched GO terms and pathways of the DEGs.

  ID                                                                   Term         Description                                 Count   P-value
  -------------------------------------------------------------------- ------------ ------------------------------------------- ------- -------------
  BP                                                                   GO:0008150   Biological process                          264     4.79E-21
  BP                                                                   GO:0044707   Single-multicellular organism process       126     1.84E-06
  BP                                                                   GO:0044699   Single-organism process                     203     1.84E-06
  BP                                                                   GO:0009987   Cellular process                            230     1.84E-06
  BP                                                                   GO:0032501   Multicellular organismal process            127     5.99E-06
  CC                                                                   GO:0005575   Cellular component                          284     2.26E-06
  CC                                                                   GO:0016020   Membrane                                    162     9.97E-05
  CC                                                                   GO:0044425   Membrane part                               131     0.00042334
  CC                                                                   GO:0044459   Plasma membrane part                          54    0.00042334
  CC                                                                   GO:0005615   Extracellular space                           30    0.00042334
  MF                                                                   GO:0003674   Molecular function                          247     9.38E-17
  MF                                                                   GO:0005515   Protein binding                             139     7.67E-05
  MF                                                                   GO:0005488   Binding                                     195     0.000128045
  MF                                                                   GO:0016491   Oxidoreductase activity                       22    0.004818428
  MF                                                                   GO:0008509   Anion transmembrane transporter activity      11    0.00600053
  KEGG                                                                 hsa00564     Glycerophospholipid metabolism                6     0.005474129
  KEGG                                                                 hsa01100     Metabolic pathways                            30    0.009706045
                                                                                                                                        
  B, Top five GO terms and pathways of the downregulated DEGs in ACT                                                                    
                                                                                                                                        
  BP                                                                   GO:0044763   Single-organism cellular process            213     1.08E-26
  BP                                                                   GO:0044699   Single-organism process                     222     4.03E-26
  BP                                                                   GO:0000278   Mitotic cell cycle                            55    7.10E-22
  BP                                                                   GO:0006950   Response to stress                          108     2.27E-21
  BP                                                                   GO:0008150   Biological process                          242     5.54E-20
  CC                                                                   GO:0044421   Extracellular region part                     69    8.67E-25
  CC                                                                   GO:0005576   Extracellular region                          88    2.08E-20
  CC                                                                   GO:0031012   Extracellular matrix                          37    2.79E-18
  CC                                                                   GO:0005615   Extracellular space                           50    1.69E-17
  CC                                                                   GO:0005578   Proteinaceous extracellular matrix            33    5.96E-17
  MF                                                                   GO:0003674   Molecular function                          234     4.95E-16
  MF                                                                   GO:0005515   Protein binding                             161     5.84E-16
  MF                                                                   GO:0005488   Binding                                     203     4.91E-12
  MF                                                                   GO:0008017   Microtubule binding                           16    1.28E-09
  MF                                                                   GO:0015631   Tubulin binding                               17    1.45E-08
  KEGG                                                                 hsa04512     Extracellular matrix-receptor interaction     14    7.14E-10
  KEGG                                                                 hsa05150     *Staphylococcus aureus* infection               8   8.10E-06
  KEGG                                                                 hsa04510     Focal adhesion                                14    1.24E-05
  KEGG                                                                 hsa04060     Cytokine-cytokine receptor interaction        16    1.44E-05
  KEGG                                                                 hsa04610     Complement and coagulation cascades             8   1.56E-05

ACT, anaplastic thyroid carcinoma; DEGs, differentially expressed genes; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; BP, biological process; MF, molecular function; CC, cellular component.

###### 

Top five enriched GO terms and pathways of differentially expressed genes in the significant modules.

  ID                                                               Term         Description                                  Count   P-value
  ---------------------------------------------------------------- ------------ -------------------------------------------- ------- ----------------------
  BP                                                               GO:0007049   Cell cycle                                   57      5.95E-49
  BP                                                               GO:0000278   Mitotic cell cycle                           49      5.95E-49
  BP                                                               GO:0022402   Cell cycle process                           52      2.58E-47
  BP                                                               GO:0051301   Cell division                                36      7.19E-37
  BP                                                               GO:0000280   Nuclear division                             32      8.81E-36
  CC                                                               GO:0005819   Spindle                                      23      2.20E-26
  CC                                                               GO:0015630   Microtubule cytoskeleton                     31      5.69E-23
  CC                                                               GO:0000793   Condensed chromosome                         18      3.83E-22
  CC                                                               GO:0000775   Chromosome, centromeric region               16      8.06E-20
  CC                                                               GO:0000777   Condensed chromosome kinetochore             13      7.98E-19
  MF                                                               GO:0005515   Protein binding                              56      6.33E-13
  MF                                                               GO:0008017   Microtubule binding                          12      6.33E-13
  MF                                                               GO:0015631   Tubulin binding                              12      1.81E-11
  MF                                                               GO:0003777   Microtubule motor activity                     8     4.83E-10
  MF                                                               GO:0005524   ATP binding                                  23      6.79E-10
  KEGG                                                             hsa04110     Cell cycle                                     8     8.20114825913878e-10
                                                                                                                                     
  B, Top five enriched GO terms and pathways of DEGs in module B                                                                     
                                                                                                                                     
  BP                                                               GO:0006935   Chemotaxis                                   11      6.44E-14
  BP                                                               GO:0042330   Taxis                                        11      6.44E-14
  BP                                                               GO:0006954   Inflammatory response                          9     4.30E-11
  BP                                                               GO:0040011   Locomotion                                   11      1.21E-10
  BP                                                               GO:0009605   Response to external stimulus                11      1.54E-10
  CC                                                               GO:0005615   Extracellular space                            7     9.36E-06
  CC                                                               GO:0044421   Extracellular region part                    7       3.43E-05
  CC                                                               GO:0005576   Extracellular region                           8     0.000169765
  CC                                                               GO:0044459   Plasma membrane part                         6       0.004168711
  CC                                                               GO:0005886   Plasma membrane                                8     0.012325713
  MF                                                               GO:0008009   Chemokine activity                             7     3.55E-15
  MF                                                               GO:0042379   Chemokine receptor binding                     7     5.71E-15
  MF                                                               GO:0001664   G-protein coupled receptor binding             7     3.54E-11
  MF                                                               GO:0005125   Cytokine activity                              7     4.17E-11
  MF                                                               GO:0005126   Cytokine receptor binding                      7     4.20E-11
  KEGG                                                             hsa04062     Chemokine signaling pathway                    8     7.14E-10
  KEGG                                                             hsa04060     Cytokine-cytokine receptor interaction         8     8.10E-06
                                                                                                                                     
  C, Top five enriched GO terms and pathways of DEGs in module C                                                                     
                                                                                                                                     
  BP                                                               GO:0030198   Extracellular matrix organization            13      1.57E-16
  BP                                                               GO:0043062   Extracellular structure organization         13      1.57E-16
  BP                                                               GO:0022617   Extracellular matrix disassembly               9     5.02E-15
  BP                                                               GO:0030574   Collagen catabolic process                     8     1.12E-13
  BP                                                               GO:0044243   Multicellular organismal catabolic process     8     1.93E-13
  CC                                                               GO:0044421   Extracellular region part                    18      4.69E-16
  CC                                                               GO:0031012   Extracellular matrix                         13      8.60E-15
  CC                                                               GO:0005581   Collagen                                       9     8.60E-15
  CC                                                               GO:0005578   Proteinaceous extracellular matrix           12      4.04E-14
  CC                                                               GO:0044420   Extracellular matrix part                    10      4.80E-14
  MF                                                               GO:0005515   Protein binding                              17      0.002325685
  KEGG                                                             hsa05142     Chagas disease (American trypanosomiasis)      7     1.8408112078959e-08

DEGs, differentially expressed genes; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; BP, biological process; MF, molecular function; CC, cellular component.

###### 

29 enriched significant pathways in the latent pathway identification analysis network.

  Path ID    Description
  ---------- ----------------------------------------------------
  hsa04512   Estraceelular matrix-receptor interaction
  hsa04974   Protein digestion and absorption
  hsa04060   Cytokine-cytokine receptor interaction
  hsa05150   *Staphylococcus aureus* infection
  hsa04610   Complement and coagulation cascades
  hsa05146   Amoebiasis
  hsa05323   Rheumatoid arthritis
  hsa04380   Osteoclast differentiation
  hsa04062   Chemokine signaling pathway
  hsa04620   Toll-like receptor signaling pathway
  hsa04145   Phagosome
  hsa04640   Hematopoietic cell lineage
  hsa04510   Focal adhesion
  hsa04670   Leukocyte transendothelial migration
  hsa05144   Malaria
  hsa04350   Transforming growth factor-β signaling pathway
  hsa05142   Chagas disease (American trypanosomiasis)
  hsa04110   Cell cycle
  hsa04971   Gastric acid secretion
  hsa05412   Arrhythmogenic right ventricular cardiomyopathy
  hsa04514   Cell adhesion molecules
  hsa00564   Glycerophospholipid metabolism
  hsa05414   Dilated cardiomyopathy
  hsa00240   Pyrimidine metabolism
  hsa05200   Pathways in cancer
  hsa01100   Metabolic pathways
  hsa04020   Calcium signaling pathway
  hsa04010   Mitogen-activated protein kinase signaling pathway
  hsa04080   Neuroactive ligand-receptor interaction

###### 

Interacting pairs of pathways with top 10 weights.

  Pathway 1 and description                   Pathway 2 and description                Weight        Co-genes
  ------------------------------------------- ---------------------------------------- ------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  hsa05323:                                   hsa04620:                                0.492651941   CTSK^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/CTSO^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/FOS/IL8^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/TLR2^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^
  Rheumatoid arthritis                        Toll-like receptor signaling pathway                   
  hsa05142:                                   hsa04620:                                0.464920784   IL8^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/TLR2^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/FOS
  Chagas disease (American trypanosomiasis)   Toll-like receptor signaling pathway                   
  hsa05146:                                   hsa04620:                                0.37284676    IL8^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/TLR2^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/CD14^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^
  Amoebiasis                                  Toll-like receptor signaling pathway                   
  hsa04620                                    hsa04060:                                0.351558647   IL8^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/CXCL10^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^
  Toll-like receptor signaling pathway        Cytokine-cytokine receptor interaction                 
  hsa04062:                                   hsa04060:                                0.33933744    CCR1^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/CXCL1^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/CXCL3^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/IL8^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/
  Chemokine signaling pathway                 Cytokine-cytokine receptor interaction                 CXCL10^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/CCL28/CCL8^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/CCL13^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/CCL18^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/CCL21/CXCL5^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^
  hsa04380:                                   hsa04620:                                0.327230722   CTSK^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/FOS
  Osteoclast differentiation                  Toll-like receptor signaling pathway                   
  hsa04974:                                   hsa04512:                                0.31737287    COL5A1^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/COL6A3^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/COL11A1^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/
  Protein digestion and absorption            ECM-receptor interaction                               COL5A3^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^
  hsa04512:                                   hsa04510:                                0.307854633   COL5A1^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/COL6A3^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/COL11A1^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/
  ECM-receptor interaction                    Focal adhesion                                         COMP^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/TNC^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/IBSP^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/ITGA2^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/ITGA4^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/ITGA5^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/LAMB3^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/COL5A3^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/RELN/SPP1^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/THBS2^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/
  hsa04145:                                   hsa04620:                                0.305699295   TLR2^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/CD14^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^
  Phagosome                                   Toll-like receptor signaling pathway                   
  hsa05150:                                   hsa04610:                                0.272281647   CFD/C1QA^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/C1QB^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/C1QC^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/
  *Staphylococcus aureus* infection           Complement and coagulation cascades                    C3AR1^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^/C5AR1^[a](#tfn3-ol-0-0-5447){ref-type="table-fn"}^

Downregulated differentially expressed genes. ECM, extracellular matrix.
